Cipla Shares Fall Amid Temporary Halt in Lanreotide Production and Earnings Concerns

Cipla's shares declined sharply following a temporary halt in production of Lanreotide Injection, a key US product, due to USFDA observations at its Greek manufacturing partner Pharmathen. The pause aims to support remediation efforts, with supply expected to resume in the first half of FY27. Brokerages have downgraded Cipla's stock and lowered earnings forecasts, citing risks from supply disruptions, competition, and exclusivity expiries, which may impact performance through FY27 and FY28.